Funding
Equity financing · Biotech

Biossil raises $153 million led by OpenAI Startup Fund

Biossil will expand clinical development and acquire additional drug candidates.

By RoundOS Funding desk

Toronto-based Biossil raised $153 million in equity financing led by OpenAI Startup Fund, valuing the company at $1 billion. CEO Anthony Mouchantaf confirmed the financing to BetaKit on September 28.

The company uses AI to identify opportunities in discontinued drug programs, then acquires or licenses candidates for further development. The funding will support clinical capacity and additions to its pipeline.

Funding history

Equity financing · This round$153M

Sources

  1. biossil-betabetakit.com · Sep 28, 2026

Similar rounds

All Biotech rounds →
ALLOX

ALLOX combines high-throughput genetics, experimental biology and AI to find functional sites on proteins and develop targeted small-molecule medicines.

$10.5MSeed · Oct 29, 2026
Dren Bio

Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.

$350MPrivate financing · Oct 29, 2026
BioGeometry

BioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering.

UndisclosedSeries A+ · Oct 28, 2026
IntegriCulture

IntegriCulture develops cell-culture systems and production technology for cellular foods, cosmetics and other biological materials.

UndisclosedFunding round · Oct 28, 2026

Related